Skip to main content
. 2022 Aug;11(8):1526–1539. doi: 10.21037/tlcr-22-192

Figure 1.

Figure 1

Immunohistochemical expression pattern of lipofuscin accumulation (A,E,I), p16INK4a (B,F,J), p21WAF1/Cip1 (C,G,K) and Ki67 (D,H,L) at ×200 magnification on sequential and adjacent FFPE sections. Left and right panels represent stainings from two NSCLC patients with an SS with high-level lipofuscin accumulation (A,I), high p16INK4a (B,J) and p21WAF1/Cip1 (C,K) expression (≥30% NSCLC cells positive) and low Ki67 expression (<30% NSCLC cells positive) (D,L). Left panels represent stainings from a NSCLC patient who did not receive any neoadjuvant therapy, whereas right panels represent stainings from a NSCLC patient who did receive neoadjuvant therapy (i.e., cisplatin-based chemotherapy). Middle panels represent stainings from a NSCLC patient showing no SS, with low-level lipofuscin accumulation (E), low p16INK4a (F) and p21WAF1/Cip1 (G) expression (<30% NSCLC cells positive) and high Ki67 expression (≥30% NSCLC cells positive) (H). SS, senescence signature; FFPE, formalin-fixed paraffin-embedded; NSCLC, non-small cell lung cancer.